CeGaT, Center for Genomics and Transcriptomics, is a sequencing and diagnostics company. As such we offer the decoding of genetic information and its medical interpretation. CeGaT’s top priority is to identify disease-causing variants in patients. In 2010 we became the first company to establish high-throughput sequencing in human genetic diagnostics, enabling us to perform the analysis of many regions of the genome simultaneously.
Our portfolio ranges from single exon interpretation using Sanger sequencing to next-generation sequencing-based whole genome analysis, and can be complemented using deletion/duplication testing by MLPA, qPCR, and Array-CGH. Our area of expertise is in the use of large Diagnostic Panels that cover all disease-specific genes; for instance all 639 genes associated with epilepsy, metabolic and brain developmental disorders. All steps are carried out by our interdisciplinary team of experts. The medical report provides the referring physician with a detailed diagnosis and support for further treatment decisions. In addition, the report provides a basis for patient and family genetic counseling.
Aside from our diagnostic endeavors, we offer numerous services for research organizations, and are contributing to publicly funded research projects, both nationally and internationally. Using various automated platforms, distinct sequencing platforms and various established laboratory protocols, in combination with custom bioinformatics analysis options, we can provide an individual solution for each request. All of our services are fully accredited according to DIN EN ISO 15189:2014 and College of American Pathologists (CAP).
Biotech CompaniesAnalytics, Bioinformatics, DNA/RNA, Biotech Services, Contract Research & Development, Diagnostics
Further information on the websites of BIOPRO Baden-Württemberg: